Navigation Links
MGT Capital Investments, Inc. Reports Fiscal 2008 Financial Results and Provides an Update on Recent Developments
Date:4/3/2009

NEW YORK, April 3 /PRNewswire-FirstCall/ -- MGT Capital Investments, Inc. (NYSE AMEX: MGT), a holding company, today reported financial results for the year ended December 31, 2008 and provided an update on strategic milestones.

For the year ended December 31, 2008 MGT Capital Investments, Inc. reported total revenue of $354,000 compared to $89,000 for the year ended December 31, 2007. Total operating expenses for the year December 31, 2008 were $29.7 million, compared to total operating expenses of $22.0 million in the comparable period for 2007. For the year ended December 31, 2008 net loss was $20.0 million, or ($0.60) per basic and diluted share, compared to a net loss of $13.8 million, or ($0.35) per basic and diluted share, for the same period in 2007. Net loss per share for the year ended December 31, 2008 was based on a weighted average of 33,188,294 million shares outstanding, compared to a weighted average of 38,900,383 million shares outstanding for the comparable period in 2007.

As of December 31, 2008 cash, cash equivalents and marketable securities were $40.2 million compared to $94.6 million at December 31, 2007. The decrease in the cash balance is primarily attributable to general operations, preparing the products for regulatory approval and a share buy-back program. In addition, exchange rates during the year impacted cash and cash equivalents as the U.S. dollar strengthened, reducing the value of these assets by approximately $10.1 million.

"MGT's operating costs for 2008 increased 35% compared to last year predominantly as a result of expanded commercial operations for Medicsight. The increase in Medicsight's operating expenses was to generate greater market awareness of Medicsight's ColonCAD software and move through the regulatory processes in the U.S. and Japan. We have started to experience increased ColonCAD sales in Europe and have already been granted regulatory approval in Canada, Australia, China, and Brazil," stated Tim Paterson-Brown, MGT Capital Investments, Inc.'s Chairman and CEO.

"Medicsight made significant progress during the year in its applications for US FDA and Japanese MHLW regulatory approvals. Its ColonCAD software is in the final stages of the Japanese regulatory approval process and recently submitted a response to an information request from the FDA. We hope to have an update on both the US and Japanese submissions by mid-2009."

"With approximately $40.2 million in cash, cash equivalents and marketable securities as of December 31, 2008 we are confident in MGT's ability to persevere through the current economic downturn and move Medicsight's ColonCAD software through the regulatory process and launch in the US and Japan."

"Medicsight is our principal investment holding at this time. We are currently reviewing opportunities to maximize our value in Medicsight and our other holdings," concluded Mr. Paterson-Brown.

About MGT Capital Investments, Inc.

MGT Capital Investments, Inc. is a holding company. The Company has two subsidiaries, Medicsight and Medicexchange.

Medicsight PLC (AIM: MDST) is a leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerized tomography (CT) scans of the colon and lung, helping radiologists to identify, measure and analyze potential disease and early indicators of disease. Medicsight's CAD software has been validated using one of the world's largest and most population diverse databases of verified patient CT scan data. Medicsight's ColonCAD(TM) and LungCAD(TM) software products are seamlessly integrated with the advanced 3D visualization workstations of several industry-leading imaging equipment partners.

Medicexchange provides medical imaging professionals with a global web portal containing an online sales, jobs and information channel for diagnostic, treatment and surgery planning solutions. This combined with a variety of relevant clinical papers, training materials and content gives these professionals access to information and products that they otherwise would have difficulty accessing.

Additional information can be found at www.mgtci.com.

All forward-looking statements are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current management expectations that involve risks and uncertainties that may result in such expectations not being realized. Potential risks and uncertainties include, but are not limited to, the risks described in company filings with the Securities and Exchange Commission.


'/>"/>
SOURCE MGT Capital Investments, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Golub Capital Provides Debt Financing to Support the Acquisition of Network Express, Inc., by Ace Expediters, Inc.
2. ReGear Life Sciences Closes $2.5 Million in Series A Financing Following $1M Investment by Stonewood Capital Management, Inc.
3. Capital BlueCross Reaches Out to Families of Uninsured Children
4. BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches
5. Elekta Finds New Interest in Leasing Solutions as Hospitals Debate Capital Purchases
6. NASDAQ Panel Grants Extension to DATATRAK for Continued Listing on the NASDAQ Capital Market
7. Abaxis, Inc. to Attend Lazard Capital Markets Medical Technologies Conference
8. Wyclef Jean and Miri Ben-Ari to Lead Phoenix House Tribute to Lisa Ellis of Fireman Capital Partners and Carnival House Recordings
9. InstaMed Announces Osage Partners and Ashby Point Capital Have Joined Existing Investors in $6 Million Growth Equity Financing
10. LeAnn Rimes Shares Her Personal Struggle With Psoriasis in Nations Capital
11. Amgen to Present at the Barclays Capital Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... 13, 2017 , ... “The Journey: From the Mountains to the Mission Field”: ... souls in the Philippines. “The Journey: From the Mountains to the Mission Field” is ... Bible. She has taught all ages and currently teaches a class of ladies at ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Mohebi Hair Restoration, has recently contributed a medical article to the newly revamped ... cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations ... literacy software tool, and the Cancer Patient Education Network (CPEN), an independent professional ... announce a new strategic alliance. , As CPEN’s strategic partner, HLI will ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... SAN DIEGO , Oct. 12, 2017   Divoti ... Medical Alert Jewelry up to the standard of the latest FDA ... (Launched: June 2017). Anyone in need of Medical ID ... Divoti Medical Alert Jewelry are engraved in terms of the ... ...
(Date:10/11/2017)... 11, 2017  BioPharmX Corporation (NYSE MKT: BPMX) researchers ... an innovative way to use nonlinear optical imaging to ... new drugs. ... will show how researchers from BioPharmX and the Wellman ... used a suite of imaging techniques in what is ...
(Date:10/11/2017)... , Oct. 11, 2017  True Health, ... has amplified its effort during National Breast Cancer ... hereditary cancer risks. ... Clinical Oncology calculated that more than 10 million ... inherited mutations in BRCA1 or BRCA2 and have not ...
Breaking Medicine Technology: